SkinBioTherapeutics (LON:SBTX) has commenced its human study. Its SkinBiotix skin treatment technology will undergo the human study.
The life science company focused on skin health has announced the three elements to the human study. First, the study will assess skin irritancy. Next, the study will assess moisturisation potential. Finally, it will assess the technology’s impact on the barrier function. Indeed, the first section of the study is already under way. The second and third are due to commence in September and November respectively.
SkinBiotix is the company’s proprietary platform technology. Additionally, SkinBioTherapeutics targets three specific skin healthcare sectors – cosmetics, infection control and eczema.
Moreover, its main shareholders are OptiBiotix Health (LON:OPTI) and Seneca.
CEO of SkinBioTherapeutics, Dr Cath O’Neill, said:
“I am delighted that we now have all three aspects of our human study scheduled.”
“Data from the two initial tests is expected in October 2018, and data from the third, larger test, is expected in Q4 2018 and Q1 2019.
“We hope that these results will provide additional proof of the SkinBiotix technology’s efficacy and enable us to continue to pursue commercial discussions”.
At 12:44 BST today, shares in SkinBioTherapeutics were trading at -6.99%.
